What is HC Wainwright’s Forecast for PDSB Q1 Earnings?

PDS Biotechnology Corporation (NASDAQ:PDSB) – Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for PDS Biotechnology in a report released on Tuesday, March 31st. HC Wainwright analyst J. Pantginis expects that the company will earn ($0.15) per share for the quarter. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for PDS Biotechnology’s Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.18) EPS and Q4 2026 earnings at ($0.20) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PDS Biotechnology in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.00.

PDS Biotechnology Stock Up 0.2%

Shares of NASDAQ PDSB opened at $0.61 on Wednesday. The stock has a market cap of $33.84 million, a PE ratio of -0.81 and a beta of 1.20. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 1.26. PDS Biotechnology has a 12-month low of $0.51 and a 12-month high of $1.92. The company has a 50-day moving average of $0.70 and a 200 day moving average of $0.85.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.06.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Armistice Capital LLC purchased a new stake in shares of PDS Biotechnology in the fourth quarter valued at about $2,182,000. Inspirion Wealth Advisors LLC raised its stake in PDS Biotechnology by 338.5% during the third quarter. Inspirion Wealth Advisors LLC now owns 344,394 shares of the company’s stock worth $348,000 after purchasing an additional 265,862 shares during the period. Squarepoint Ops LLC boosted its holdings in PDS Biotechnology by 116.1% in the 3rd quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after purchasing an additional 156,662 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in PDS Biotechnology by 117.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after purchasing an additional 106,300 shares during the last quarter. Finally, Susquehanna International Group LLP grew its stake in shares of PDS Biotechnology by 603.7% in the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after buying an additional 80,937 shares during the period. Institutional investors and hedge funds own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.